Celestica: Free Cash Flow Tells The Whole Story

Celestica reported Q3 revenue growth of 83% year over year and EPS growth of 109%, beating consensus, and raised its 2027 guidance to $40B in revenue and $21.5 in non-GAAP EPS. However, it expects negative free cash flow in 2027 from heavy working-capital investment, while cash conversion is deteriorating; recent FCF has been supported by receivables sales, and payables growth has only matched inventory increases.

Analysis

The key issue is not whether demand is strong, but whether growth is converting into cash. Receivables sales can pull cash forward, while payables merely keeping pace with inventory suggests suppliers are not funding the incremental build. If this pattern persists, reported EPS may overstate the economic return on growth and could eventually raise funding needs or constrain capacity; neither is established by the current data. The near-term earnings reaction can remain positive, but over the next 1–3 months investors should scrutinize receivables-sale dependence, DSO, inventory turns and customer payment terms. A sustained gap between earnings and operating cash generation raises the risk of a quality-of-earnings discount, especially if 2027 growth requires continued working-capital absorption. Over 6–18 months, the bull case is that inventory converts and cash conversion normalizes as the ramp matures. The bear case is that customer demand or delivery timing slips, leaving inventory and receivables elevated while the company still pursues its growth plan. This is not yet a clean short: strong execution may justify a premium, and the article supplies no valuation, balance-sheet, customer-mix or working-capital detail. The market may be underweighting cash-flow quality, but the scale and duration of the cash drain remain unverified.

Key Decisions for Investors

• Avoid chasing CLS solely on EPS and guidance; treat the cash-conversion profile as the gating variable for adding exposure.
• For existing CLS longs, consider trimming or hedging into strength if subsequent disclosures show rising receivables-sale use, worsening DSO, or inventory outpacing revenue. Reassess if operating cash flow improves without relying on receivables sales.
• Watch the next quarterly filings for receivables sold, DSO, inventory turns, operating cash flow versus earnings, and any financing or balance-sheet commentary; verify whether the working-capital build is temporary and tied to customer ramps.
• A relative-value short against CLS is not yet supported: first compare cash conversion and exposure to the same electronics-manufacturing demand cycle at competitors such as Jabil and Flex. Falsification of the cautious thesis would be inventory conversion and improving cash generation alongside maintained guidance.